高度的VIII因子会干扰体外葡萄糖蛋白VI介导的血小板激活
Rohini Sekar1, Angelina Mimoun1, Melissa Bou-Jaoudeh1
1Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique, Sorbonne Université, Université Paris Cité, Paris, France.
Journal of thrombosis and haemostasis : JTH
|February 7, 2024
概括
无维莱布兰德因子的第八因子 (FVIII) 与血小板糖蛋白VI (GPVI) 结合,抑制原诱导的血小板聚合. 这种相互作用可能是控制血小板激活的负反机制.
科学领域:
- 血液学 血液学 血液学
- 血栓形成和血液静止.
- 血小板生物学 血小板生物学
背景情况:
- 激活的第八因子 (FVIII) 招募到激活的血小板,对血管损伤部位的血栓素和纤维素产生至关重要.
- 已知FVIII与血小板结合,特别是激活的血小板结合,但其生理相关性尚不清楚.
- 血小板激活涉及复杂的信号通路,与凝血因子的相互作用可以调节这些.
研究的目的:
- 为了研究因子VIII (FVIII) 与血小板相互作用的影响.
- 描述FVIII.III对血小板功能的潜在调节.
- 探索FVIII-血小板相互作用背后的分子机制.
主要方法:
- 用FVIII化洗净的血小板.
- 使用流细胞计和光传输聚合计评估血小板激活.
- 通过Western blot对酸化配置文件的下游信号通路的分析.
- 使用ELISA,共聚焦显微镜和近距离结合试验,研究FVIII-GPVI相互作用.
主要成果:
- FVIII证明了对静止和激活血小板的剂量依赖的结合.
- 超生理学FVIII度抑制了原诱导的血小板聚合,而没有引起自发激活.
- 没有VWF的FVIII与血小板GPVI密切相互作用,改变了GPVI依赖的酸化.
结论:
- 无VWF的FVIII与GPVI结合或接近GPVI,可以在体外调节血小板激活.
- 这种相互作用表明潜在的负反循环来调节过度的血小板激活.
- 需要进一步的体内研究来确定血管损伤部位的FVIII度是否支持这种调节功能.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
01:22Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
01:24Disorders of Hemostasis
915
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
915
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525